Julia Strandberg - Jan 14, 2023 Form 4 Insider Report for Pear Therapeutics, Inc. (PEARQ)

Role
Chief Commercial Officer
Signature
/s/ Stacie S. Aarestad, Attorney-in-Fact
Stock symbol
PEARQ
Transactions as of
Jan 14, 2023
Transactions value $
$0
Form type
4
Date filed
1/18/2023, 04:01 PM
Previous filing
Feb 18, 2022
Next filing
Jan 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PEARQ Common Stock Options Exercise $0 +33K +397.59% $0.00 41.3K Jan 14, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PEARQ Restricted Stock Units Options Exercise $0 -33K -33% $0.00 67K Jan 14, 2023 Common Stock 33K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 8,300 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 30, 2022.
F2 Each restricted stock unit represents a contingent right to receive one share of PEAR common stock.
F3 The remaining restricted stock units shall vest and settle as to 33% of the shares on January 14, 2024 and 34% on January 14, 2025.